Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung Cancer

Clinical trial NCT06525246 · COMPLETED

Trial details

NCT number: NCT06525246
Sponsor: Ono Pharmaceutical Co., Ltd.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Stage IIIB Non-small Cell Lung Cancer Stage IIIC Non-Small Cell Lung Cancer Stage IV Non-small Cell Lung Cancer Recurrent Non-Small Cell Lung Cancer EGFR Mutation-Related Tumors

Start date: 2021-08-06
Primary completion: 2025-06-23
Enrollment: 78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.